• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

House Dems launch MS drug pricing probe

August 17, 2017 By Sarah Faulkner

capitol hillDemocrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of an investigation into why prices for multiple sclerosis drugs have nearly quadrupled since 2004.

Reps. Elijah Cummings (D-Md.) and Peter Welch (D.-Mass) penned inquiries to Bayer (ETR:BAYN), Biogen (NSDQ:BIIB), EMD Serono, Novartis (NYSE:NVS), Roche (OTC:RHHBY), Sanofi Aventis (NYSE:SNY) and Teva Pharmaceuticals (NYSE:TEVA).

In these letters, the U.S. representatives cited a study which claims that some drugmakers appear to be hiking the prices of their products in lockstep with competitors – a practice known as “shadow pricing.”

In other words, when one company launches a new, more expensive product, other companies will shadow these higher prices by hiking their pricetag to match.

The lawmakers said that between 2004 and 2015, the average cost of MS therapy jumped from $16,050 to $60,000.

“We are launching an in-depth investigation to determine why drug companies are dramatically increasing their prices for drugs used to treat Multiple Sclerosis (MS), which is a disease of the central nervous system that often has devastating and disabling effects on patients,” Cummings and Welch wrote.  “We believe no American should be forced to struggle to afford lifesaving medical treatments, especially when drug companies increase prices without warning, cause, or justification.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Bayer AG, Biogen Idec, Capitol Hill, Novartis, Roche, Sanofi-Aventis, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS